AZTR
Price
$0.07
Change
-$0.05 (-41.67%)
Updated
Oct 13 closing price
Capitalization
4.33M
20 days until earnings call
Intraday BUY SELL Signals
QNTM
Price
$2.27
Change
-$0.13 (-5.42%)
Updated
Oct 22 closing price
Capitalization
18.36M
15 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AZTR vs QNTM

AZTR vs QNTM Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
AZTR vs. QNTM commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZTR is a Hold and QNTM is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for AZTR with price predictions
Oct 22, 2026

AZTR's Stochastic Oscillator is staying in oversold zone for 17 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

Following a +6.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZTR advanced for three days, in 116 of 144 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

AZTR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

AZTR moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for AZTR crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 6 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZTR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for AZTR entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.591) is normal, around the industry mean (2.973). P/E Ratio (3.575) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (146.534) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. AZTR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AZTR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for QNTM with price predictions
Oct 22, 2026

QNTM in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 05, 2026

QNTM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 34 cases where QNTM's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +8.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where QNTM advanced for three days, in 194 of 228 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QNTM as a result. In 59 of 65 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for QNTM turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 35 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

QNTM moved below its 50-day moving average on October 05, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for QNTM crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 19 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where QNTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for QNTM entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.309) is normal, around the industry mean (2.973). P/E Ratio (-0.506) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. QNTM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QNTM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
QNTM: Fundamental Ratings
QNTM
OUTLOOK RATING
1..100
75
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
87
P/E GROWTH RATING
1..100
17
SEASONALITY SCORE
1..100
22

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AZTRQNTM
RSI
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
87%
Momentum
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 18 days ago
81%
Bullish Trend 29 days ago
85%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (AZTR: $0.07 vs. QNTM: $2.27)
Brand notoriety: AZTR and QNTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AZTR: 148% vs. QNTM: 97%
Market capitalization -- AZTR: $4.33M vs. QNTM: $18.36M
AZTR [@Biotechnology] is valued at $4.33M. QNTM’s [@Biotechnology] market capitalization is $18.36M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AZTR’s FA Score shows that 1 FA rating(s) are green while QNTM’s FA Score has 1 green FA rating(s).

  • AZTR’s FA Score: 1 green, 4 red.
  • QNTM’s FA Score: 1 green, 4 red.
According to our system of comparison, both AZTR and QNTM are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AZTR’s TA Score shows that 4 TA indicator(s) are bullish while QNTM’s TA Score has 4 bullish TA indicator(s).

  • AZTR’s TA Score: 4 bullish, 4 bearish.
  • QNTM’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, AZTR is a better buy in the short-term than QNTM.

Price Growth

AZTR (@Biotechnology) experienced а 0.00% price change this week, while QNTM (@Biotechnology) price change was -16.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

AZTR is expected to report earnings on Nov 11, 2026.

QNTM is expected to report earnings on Nov 06, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
AZTR
Daily Signal:
Gain/Loss:
QNTM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

AZTR and

Correlation & Price change

A.I.dvisor indicates that over the last year, AZTR has been closely correlated with DARE. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if AZTR jumps, then DARE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AZTR
1D Price
Change %
AZTR100%
N/A
DARE - AZTR
73%
Closely correlated
-5.28%
PHIO - AZTR
34%
Loosely correlated
-1.13%
EYPT - AZTR
32%
Poorly correlated
-0.44%
GUTS - AZTR
28%
Poorly correlated
-1.74%
DYAI - AZTR
28%
Poorly correlated
+0.50%
More

QNTM and

Correlation & Price change

A.I.dvisor indicates that over the last year, QNTM has been loosely correlated with TNXP. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if QNTM jumps, then TNXP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QNTM
1D Price
Change %
QNTM100%
-5.42%
TNXP - QNTM
35%
Loosely correlated
-5.52%
AZTR - QNTM
29%
Poorly correlated
N/A
ATHE - QNTM
27%
Poorly correlated
-10.04%
CPIX - QNTM
26%
Poorly correlated
+3.79%
EBS - QNTM
24%
Poorly correlated
+0.48%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PSN47.802.40
+5.29%
Parsons Corp
AVO11.820.27
+2.34%
Mission Produce
ABEV3.330.06
+1.83%
Ambev SA
KROS11.350.17
+1.52%
Keros Therapeutics
MRKR1.07-0.06
-5.31%
Marker Therapeutics